Effective dose of remazolam tosylate combined with subthreshold dose of esketamine for inhibiting cardiovascular response to endotracheal intubation in the elderly

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062787

Enrollment

Unknown

Registered

2022-08-18

Start date

2022-08-15

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anesthesia induction medication

Interventions

test group:Remazolam tosylate combined with esketamine for induction of anesthesia

Eligibility

Sex/Gender

All

Age

65 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18~40 years old; 2. ASA I~II grade; 3. Full-term gestational age, 37 to 42 weeks; 4. Sign the informed consent form and cooperate with the completion of the test.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to all drugs and excipients during anesthesia and postoperative analgesia; 2. Serious obstetric complications or serious underlying diseases during pregnancy; 3. Suffering or ever suffering from mental illness; 4. Those who are dependent on drugs, alcohol, etc.; 5. Are or have been subjected to domestic violence; 6. The fetus has congenital diseases; 7. Circumstances that the investigator considers inappropriate to be included in the study.

Design outcomes

Primary

Measure	Time frame
Effective dose of remazolam tosylate for induction of anesthesia;	—

Countries

China

Contacts

Public ContactChunyan Zhao

Dazhu County People's Hospital

404654508@qq.com+86 13368296999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026